MINE (Minerco Resources, Inc.) 0.0028

MINE (Minerco Resources, Inc.) 0.0028

Contact Info

• 20 Trafalgar Square
• Suite 455
• Nashua, NH 03063

• Website: http://www.minercoresources.com
• Phone: 281-994-4187
• Email: info@minercoresources.com

Business Description

Minerco Resources, Inc., a development stage company, operates as a progress developer, producer, and provider of clean, renewable energy solutions in Latin America. It owns 100% of the rights to 2 hydro electric projects and 1 wind project in Honduras. The company was founded in 2007 and is based in Katy, Texas.

Minerco Resources, Inc. (OTC.BB: MINE), a progressive developer, producer and provider of worldwide commodities solutions, announced today that the company is adding a retail division to the company.

The new management team of the company, with the approval of the board of directors, has voted to expand the company's business model to include a progressive retail division. Based on the company's management experience and its existing presence in Central America, the company's first retail venture will be in the beverage industry, specializing in coffee and energy/vitamin drinks.

AS PER RECENT FILINGS

"Mr. Powers will be paid  a salary of $84,000 per annum beginning on February 1, 2013.  If revenues exceed $5 million, then Mr. Powers salary will be increased to $144,000 per annum.  If revenues exceed $10 million, then Mr. Powers salary will be increased to $180,000 per annum. "

"On February 20, 2013, the Company issued 15,000,000 shares of its common stock to its Chief Executive Officer pursuant to an employment agreement dated February 1, 2013"

Key Points.

-The stock seems to be forming an ascending triangle pattern
-New CEO has been hired.

-CEO will make more money in salary if the stock prices goes higher.
-CEO also owns 15 million shares. Another reason to see to a higher stock price.
-Company has a low float.

Sign up for our VIP membership for $9.99 per month. PSW is one of the best newsletters in its field. Click here to sign up and get our early alerts.

-PSW Team

MultiCell Technologies, Inc. 0.0047

Contact Info

• 68 Cumberland Street
• Suite 301
• Woonsocket, RI 02895

• Website: http://www.multicelltech.com
• Phone: 401-762-0045
• Email: info@multicelltech.com

Business Description

MultiCell Technologies, Inc., is a leading provider of liver cell-based products for drug discovery and therapeutic applications. The Company specializes in innovative cell immortalization technologies for reproducible creation of highly functional cell lines. MultiCell is now marketing liver cell lines via licensee, XenoTech, LLC and has additional pipeline products.


MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer.
Our therapeutic development platform relies on several patented technologies used to: (i) isolate, characterize and differentiate stem cells from human liver, or (ii) control the immune response at transcriptional and translational levels through dsRNA-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology, or (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway.
Our therapeutic development platform offers several key advantages:

• Selective modulation of noradrenergic neurons without influencing seratoninergic neurons to inhibit the reuptake of noradrenaline (norepinephrine) while promoting increased tyrosine hydroxylase activity for the treatment of primary multiple sclerosis-related fatigue (PMSF) affecting over 70% of all persons with multiple sclerosis (MS).
• Unlike other immune modulating compounds, our use of novel synthetic dsRNAs is not species or sequence-specific yet enables selective control of critical immune signaling pathways, and therefore has the potential in a broader spectrum of therapeutic applications as a monotherapy or in combination with other therapies.
• Coupling our synthetic double stranded RNA (dsRNA) platform technology with our therapeutic antibody technology, maximizes the potential of disease-associated epitope peptides to create a novel class of more effective anticancer therapeutics.
• The potential to isolate cancer stem cells from human liver in support of the development of novel therapeutics needed to effectively manage and treat patients with primary hepatocellular carcinoma.

Our portfolio of lead drug candidates is in various stages of discovery optimization, and preclinical and clinical development:

• MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial.
• MCT-465, a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers such as those expressing TLR-3.
• MCT-475, a discovery stage antibody therapeutic candidate used in combination with dsRNA for the treatment of solid tumor cancers.
• MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers.  

Sign up for our VIP membership for $9.99 per month. PSW is one of the best newsletters in its field. Click here to sign up and get our early alerts.

EDXC (ENDEXX Corp) 0.049

Contact Info

• PO Box 4317
• Cave Creek, AZ 85331
• Website: http://www.endexx.com

• Phone: 480-595-6900
• Email: endexxcorporation@yahoo.com

Business Description

Endexx provides an Online/Cloud based Collaboration Platform and online web-hosted document management services for publicly traded companies, private companies, small businesses, school boards and non profit organizations. Endexx services are subscription based. Endexx employs SAS70-Type II security for optimal client protection.
Endexx's subsidiary Global Solaris Group, LLC. provides Development and Implementation services in the Renewable Energy sector in both the US and International Markets with concentration in the Solar and Wind sectors and services. Endexx Corporation is developing Mobility App Solutions. Endexx is developing a cloud based Specialty Pharmacy software platform.

AS PER PR

"Endexx updates Corporate Information
Cave Creek, AZ., February 13, 2013(via OTCMarkets.com) - Endexx Corporation (OTC Markets: EDXC) announces a tier change at OTCMarkets.com. Endexx is pursuing elevated corporate transparency. Endexx’s mission is to expand its’ current software services and technology platform to enhance shareholder value and create a strong business model fostering entrepreneurship, capital growth and recurring revenue streams. Endexx will report material events and developments providing" 

Sign up for our VIP membership for $9.99 per month. PSW is one of the best newsletters in its field. Click here to sign up and get our early alerts.

SUTI (SUTIMCo International, Inc) 0.0009

SUTI (SUTIMCo International, Inc) .0009

Contact Info

515 Cabrillo Park Drive Suite 300

Santa Ana, CA 92701

Phone: 949-478-0796      

52 week low .0003

52 week high .23

Average Vol (3m) 14,136,248

 As per last filings 

Common stock; $0.001 par value; 950,000,000 shares authorized;
291,266,811 shares issued and 291,250,144 outstanding as of
September 30, 2012, and 32,637,213 shares issued and 32,617,706
outstanding as of December 31, 2011, respectively 

Business Description

SUTIMCo International, Inc. is a holding company, which utilizes a unique and established platform to launch new technology enterprises based on world-class university research discoveries. SUTIMCo International, through its wholly owned subsidiary SUTIMCo, Inc., provides experienced management to early stage companies, reducing risk and assuring the know-how in launching and growing a new company. In addition to this skilled management team, SUTIMCO can avail itself of the encyclopedic, inform...

"The SUTIMCo Difference"

SUTIMCo is a "product launch" company and it manages joint ventures between universities, investors, and itself.   Product launch is more than just product development or new product marketing.  It combines product definition, technical development, marketing and sales and human development and team building.  The output of the process is a "company" or "division" which is stand alone and can be sold.  It services clients brought to it by SUTI Holdings LP under the terms of a Venture Acceleration Agreement.   In order to be efficient the projects are jointly selected and vetted by both parties. 

"SUTIMCo's Keys to Success!"

SUTIMCo's key to success is reduced cycle time - not just time to market - but actually time to profit.             

Projects are assigned to a Business Unit.  Business Units consist of 4 projects, these business units are usually related to compatible markets or common technologies.

The Business Unit is headed by a COO with Vice Presidents of Marketing, Engineering and Administration all reporting to him.  Each of those people provides management and leadership to all four projects in the Business Unit.  Each project will have a fully dedicated VP of Business Development and the Business Unit will have 6 - 9 additional support staff, not counting specialized staff the Portfolio Company might require.  All the employees of the Business Unit are employees of SUTIMCo.

Business Units are to be placed around the country, and the goal of SUTIMCO international is to create as many Business Units as possible, since each is independent.  Presently the plan is to have Business units in Orange County California, Fairfax County Virginia, Denver Colorado, Connecticut, and Northern New Jersey with possible units in San Diego, Seattle, Orlando, Dallas and Indianapolis.

"SUTIMCo's Objective"

SUTIMCo provides dedicated, experienced support to position each of our portfolio companies for rapid commercialization. The objectives are:

• Cumulative revenues over 5 years of $150 million
• High margins      
• Accelerated prototype production
• Product design and development to take no longer than 12 months
• Cash flow breakeven by the third year
• Profitable in the third year
• Clear exit strategy

• Sign up for our VIP membership for $9.99 per month. PSW is one of the best newsletters in its field. Click here to sign up and get our early alerts.

   

Update for NTEK and VDSC

NTEK 0.018: Originally alerted at 0.0008 by us to our VIP members and general public as a special holidays play. We stated that the big rewards would be reaped early 2013. Currently this stock has shown its powerful support when bouncing quickly back in the 2 cent range after impatient investors took profit on what could be the next legendary stock that currently has the potential of hitting anywhere between the $0.10-%0.30 price range. Perhaps even more as additional developments are arranged on a timely basis. Clearly the company wants a rapid rate of grown, Penny Stock Whispers finds NANOFLIX  very interesting and this could truly be the ace in the hole. We would like to note that today after hours we saw 7,313,448 shares being bought on a Form T order. At 2 cents that is over $146,000 dollar amount. That is a clear signal on its own on the possible direction this company could be heading towards in the future.

VDSC 0.0073: Originally alerted by us at 0.0008 to our VIP members and again at 0.001 to the general public. Since then the stock has seen highs of 0.0093 then pulling back as impatient investors took profits off the table which triggered a consolidation phase. We believe that this stock could follow the NTEK path and hit the multi penny range at the very least if the company presents a more transparent image to investors. We advise investors to keep a keen eye on this stock as we suspect the company will release an update soon. Currently the stock is trading around its current support levels as investors patiently await for news.

Sign up for our VIP membership for $9.99 per month. PSW is one of the best newsletters in its field. Click here to sign up and get our early alerts.